Mealey's (October 3, 2018, 12:37 PM EDT) -- WASHINGTON, D.C. — The United States on Sept. 20 sided with Merck Sharp & Dohme that there is clear evidence that the Food and Drug Administration rejected a stronger warning about atypical femur fractures from the osteoporosis drug Fosamax, according to an amicus curiae brief filed with the U.S. Supreme Court (Merck Sharp & Dohme Corp. v. Doris Albrecht, et al., No. 17-290, U.S. Sup.)....